Allen Barnett, PhD
Lyn Dyster, PhD
David Hangauer, PhD
Johnson Lau, MD
TSC MEMBER INSTITUTION(S):
University at Buffalo
National Institutes of Health
ABOUT THE COMPANY:
Kinex Pharmaceuticals is developing next generation anti-cancer drugs that target the molecular basis of disease. The company uses a proprietary technology platform to generate compounds that inhibit the Protein Kinase and Phosphatase family of proteins.
Mimetica™ is Kinex Pharmaceuticals’ patented technology for generating small molecule inhibitors of kinases and phosphatases that bind in the substrate pocket. The key advantage of the new protein kinase inhibitors that Kinex is developing is that because of the unique binding site against which these compounds are targeted, there is a greatly reduced chance that patients will develop resistance to these drugs — a problem that already has rendered ineffective some of the first marketed protein kinase inhibitors.
UNIVERSITY-BASED RESEARCH CONNECTION:
Kinex was formed in 2003 based on the basic research of David Hangauer, PhD, associate professor of medicinal chemistry in the Department of Chemistry in University at Buffalo’s College of Arts and Sciences. Kinex is commercializing Hangauer’s unique method for designing and synthesizing anti-cancer compounds. Phase I clinical testing of Kinex’s lead compound, KX-01, has been completed. A second compound is in pre-clinical testing.
ROLE OF FEDERAL RESEARCH FUNDING:
The original research conducted at University at Buffalo was supported with funding from the National Institutes of Health.
Read The Full Report Here